February 19, 2001
Bothell Biotech Company to receive $128,000 for cancer research
Seattle Genetics, a Bothell biotech company, will receive a federal grant from the National Cancer Institute totaling over $128,000.
The grant will be used by Seattle Genetics to develop anti-cancer drugs that minimize many of the ill-effects associated with standard chemotherapy.
Seattle Genetics scientists have investigated several enzymes involved in tumor growth, which may be used to activate anti-cancer drugs once they reach tumor cells, avoiding the body's exposure to the toxicity of active drugs.